©The Author(s) 2025.
World J Orthop. Oct 18, 2025; 16(10): 110233
Published online Oct 18, 2025. doi: 10.5312/wjo.v16.i10.110233
Published online Oct 18, 2025. doi: 10.5312/wjo.v16.i10.110233
Table 1 Baseline characteristics of study participants
| Parameters | Tapentadol (n = 44) | Placebo (n = 46) | P value |
| Mean age (mean ± SD) | 61.07 ± 12.47 | 60.18 ± 11.18 | 0.75 |
| Gender (male) | 36% | 22% | 0.90 |
| Mean body weight (mean ± SD) | 63.50 ± 12.45 | 65.44 ± 11.40 | 0.46 |
| Baseline visual analog scale score for osteoarthritis, median (IQR) | 4 (4-5) | 4 (4-5) | 0.22 |
| The duration between drug administration and surgery (minutes), median (IQR) | 75.28 (62.70-78.03) | 75.87 (60.25-78.88) | 0.30 |
| Duration of surgery(minutes), median (IQR) | 68.20 (65.43-75.15) | 69.04 (66.20-72.33) | 0.16 |
| Baseline cholecystokinin levels, median (IQR) | 160.6 (138.39-206.58) | 158.35 (120.45-197.48) | 0.53 |
- Citation: Bhattacharjee S, Srinivasan A, Tripathy SK, Doki SK, Hota D. Efficacy and safety of pre-emptive tapentadol on pain control in total knee arthroplasty: A randomized, double-blind, placebo-controlled trial. World J Orthop 2025; 16(10): 110233
- URL: https://www.wjgnet.com/2218-5836/full/v16/i10/110233.htm
- DOI: https://dx.doi.org/10.5312/wjo.v16.i10.110233